Manufacturer of Controlled Substances; Notice of Application, 14841 [E8-5530]

Download as PDF Federal Register / Vol. 73, No. 54 / Wednesday, March 19, 2008 / Notices should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, VA. 22152; and must be filed no later than May 19, 2008. Dated: March 10, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–5530 Filed 3–18–08; 8:45 am] Dated: March 10, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–5528 Filed 3–18–08; 8:45 am] Manufacturer of Controlled Substances; Notice of Application DEPARTMENT OF JUSTICE Drug Enforcement Administration jlentini on PROD1PC65 with NOTICES Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on October 26, 2007, Chemica Inc., 316 West 130th Street, Los Angeles, California 90061, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of methamphetamine (1105), a basic class of controlled substance listed in schedule II. The above listed controlled substance is an intermediate in the manufacture of Benzphetamine, a schedule III nonnarcotic controlled substance. The methamphetamine will not be sold as a commercial product in the domestic market. Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537; or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than May 19, 2008. 16:50 Mar 18, 2008 Jkt 214001 DEPARTMENT OF JUSTICE Drug Enforcement Administration Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on February 29, 2008, Varian, Inc., Lake Forest, 25200 Commercentre Drive, Lake Forest, California 92630–8810, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedule II: BILLING CODE 4410–09–P VerDate Aug<31>2005 BILLING CODE 4410–09–P Drug Schedule Phencyclidine (7471) .................... 1-Piperidinocyclohexanecarbonitrile (8603). Benzoylecgonine (9180) ............... II II II The company plans to manufacture small quantities of the listed controlled substances for use in diagnostic products. Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than May 19, 2008. Dated: March 11, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–5532 Filed 3–18–08; 8:45 am] BILLING CODE 4410–09–P PO 00000 Frm 00073 Fmt 4703 Sfmt 4703 14841 DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Registration By Notice dated December 17, 2007 and published in the Federal Register on December 27, 2007 (72 FR 73358), GE Healthcare, 3350 North Ridge Avenue, Arlington Heights, Illinois 60004–1412, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of Cocaine (9041), a basic class of controlled substance listed in schedule II. The company plans to import small quantities of ioflupane, in the form of three separate analogues of Cocaine, to validate production and QC systems; for a reference standard; and for producing material for future investigational new drug (IND) submission. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of GE Healthcare to import the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated GE Healthcare to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed. Dated: March 10, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–5501 Filed 3–18–08; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Registration By Notice dated December 17, 2007 and published in the Federal Register on December 27, 2007,(72 FR 73360), Noramco Inc., 500 Swedes Landing E:\FR\FM\19MRN1.SGM 19MRN1

Agencies

[Federal Register Volume 73, Number 54 (Wednesday, March 19, 2008)]
[Notices]
[Page 14841]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-5530]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a), Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on October 26, 2007, Chemica 
Inc., 316 West 130th Street, Los Angeles, California 90061, made 
application by letter to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of methamphetamine (1105), a basic 
class of controlled substance listed in schedule II.
    The above listed controlled substance is an intermediate in the 
manufacture of Benzphetamine, a schedule III non-narcotic controlled 
substance. The methamphetamine will not be sold as a commercial product 
in the domestic market.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substance may file comments or objections 
to the issuance of the proposed registration pursuant to 21 CFR 
1301.33(a). Any such comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Drug Enforcement 
Administration, Office of Diversion Control, Federal Register 
Representative (ODL), Washington, DC 20537; or any being sent via 
express mail should be sent to Drug Enforcement Administration, Office 
of Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than May 19, 2008.

    Dated: March 10, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E8-5530 Filed 3-18-08; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.